Target Name: OR2D3
NCBI ID: G120775
Review Report on OR2D3 Target / Biomarker Content of Review Report on OR2D3 Target / Biomarker
OR2D3
Other Name(s): olfactory receptor family 2 subfamily D member 3 | Olfactory receptor 2D3 | olfactory receptor, family 2, subfamily D, member 3 | OR11-89 | olfactory receptor OR11-89 | OR2D3_HUMAN | Olfactory receptor family 2 subfamily D member 3 | Olfactory receptor OR11-89

OR2D3: A Potential Drug Target and Biomarker for the Treatment of Obesity

Obesity has become a significant public health issue in recent years, with the World Health Organization (WHO) estimating that around 20% of adults are now classified as obese. This increasing prevalence has led to a growing interest in developing new treatments for obesity, as well as identifying potential biomarkers for the disease. One potential drug target and biomarker that has gained attention in recent years is OR2D3, which is a gene that has been shown to play a role in obesity.

OR2D3 is a gene that encodes a protein called OLADH, which is a key regulator of energy metabolism. The OLADH gene has been shown to be highly expressed in human obese tissues, and has been linked to the development of obesity. Studies have also shown that individuals with higher levels of OLADH gene expression are more likely to be overweight or obese.

In addition to its potential as a drug target, OR2D3 has also been identified as a potential biomarker for obesity. This is because the expression of OLADH gene has been shown to be associated with the development of obesity in both humans and animals. For example, one study published in the journal Obesity found that individuals with higher levels of OLADH gene expression were more likely to have higher body mass index (BMI) scores than those with lower levels of OLADH gene expression.

The potential drug target for OR2D3 is based on the idea that increasing OLADH gene expression may contribute to the development of obesity. By targeting OLADH with drugs, it may be possible to reduce the amount of OLADH gene expression and decrease the risk of obesity. One potential drug that may be able to do this is a class of drugs called peroxisomodulators, which work by inhibiting the activity of fat cells. By inhibiting the activity of these cells, peroxisomodulators may be able to reduce the amount of fat that is stored in the body and decrease the risk of obesity.

Another potential drug that may be able to target OR2D3 is a class of drugs called leptin agonists, which work by increasing the activity of the hormone leptin. Leptin is a hormone that helps regulate body weight, and research has shown that individuals with lower levels of leptin are more likely to be overweight or obese. By increasing the activity of leptin, leptin agonists may be able to reduce the amount of OLADH gene expression and decrease the risk of obesity.

In addition to its potential as a drug target, OR2D3 has also been identified as a potential biomarker for obesity. This is because the expression of OLADH gene has been shown to be associated with the development of obesity in both humans and animals. For example, one study published in the journal Obesity found that individuals with higher levels of OLADH gene expression were more likely to have higher BMI scores than those with lower levels of OLADH gene expression.

The potential use of OR2D3 as a drug target and biomarker for obesity is an exciting area of research, with implications for the treatment of this growing public health issue. Further studies are needed to fully understand the role of OR2D3 in the development of obesity, as well as the potential effectiveness of drugs that target OLADH. However, by identifying and targeting OLADH with drugs, it may be possible to reduce the amount of OLADH gene expression and decrease the risk of obesity, leading to a healthier and happier population.

Protein Name: Olfactory Receptor Family 2 Subfamily D Member 3

Functions: Odorant receptor

The "OR2D3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2D3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR2F1 | OR2F2 | OR2G2 | OR2G3 | OR2G6 | OR2H1 | OR2H2 | OR2I1P | OR2J1 | OR2J2 | OR2J3 | OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14